Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...
A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.
'Mad Money' host Jim Cramer weighs in on stock including: Anavex Life Sciences, Sarepta Therapeutics, Viking Therapeutics, ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $151.64, a high estimate of ...
4d
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on SRPT stock, giving a Buy rating yesterday.Stay Ahead of the ...
Analysts at HC Wainwright raised their FY2024 earnings estimates for Sarepta Therapeutics in a note issued to investors on ...
Mizuho Securities analyst Uy Ear has assigned their bullish stance on SRPT stock, giving a Buy rating yesterday.Stay Ahead of the ...
1d
Assenagon Asset Management S.A. trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 62.2% in the ...
Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise ...
Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter ...
Sarepta Therapeutics exceeded 2024 net product revenue guidance and reaffirmed its 2025 outlook, partly due to strong growth for Duchenne muscular dystrophy drug Elevidys.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback